amiodarone has been researched along with simvastatin in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (47.22) | 29.6817 |
| 2010's | 17 (47.22) | 24.3611 |
| 2020's | 2 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Li, Y; Li, YH; Wang, YH; Yang, L; Yang, SL | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Kanitra, L; Moore, R; Mulligan, TE; Zhi, J | 1 |
| de Denus, S; Spinler, SA | 1 |
| Krähenbühl, S; Roten, L; Schlienger, RG; Schoenenberger, RA | 1 |
| Alsheikh-Ali, AA; Karas, RH | 1 |
| Chakrabarti, S; Chouhan, UM; Millward, LJ | 1 |
| Guirguis, A; Ricaurte, B; Taylor, HC; Zabriskie, D | 1 |
| Becquemont, L; Funck-Brentano, C; Jaillon, P; Letierce, A; Neuvonen, M; Neuvonen, PJ; Verstuyft, C | 1 |
| Van Gelder, IC | 1 |
| Azizi, M; Behrens, S; Hashagen, S; Nägele, H | 1 |
| Dias-Neto, E; Ojopi, EB; Perini, JA; Rangel, F; Santana, IS; Silva-Assunção, E; Struchiner, CJ; Suarez-Kurtz, G | 1 |
| Boucher, BJ | 1 |
| Beckey, C; Hough, A; Karimi, S; Parra, D | 1 |
| DeDea, L | 1 |
| Chen, WQ; Chen, WS; Gao, BR; Guan, XQ; Li, ZZ; Xu, ZY; Yang, K; Zhang, YH | 1 |
| Kasbekar, N; Prom, R; Spinler, SA; Umscheid, CA | 1 |
| Filipovic, M; Müller-Höcker, C; Pietsch, U | 1 |
| Dhayat, NA; Semmo, M | 1 |
| Chyou, TY; Nishtala, PS | 1 |
| Coleman, MD; Izotov, BN; Kteniadakis, S; Papadakis, GZ; Spandidos, DA; Stancioiu, F; Tsatsakis, A | 1 |
| Ainsworth, M; Bookstaver, D; Gleaton, M; Milner, E | 1 |
2 review(s) available for amiodarone and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A dissection of SARS‑CoV2 with clinical implications (Review).
Topics: Amiodarone; Animals; COVID-19; Curcumin; Humans; Pioglitazone; Respiratory Distress Syndrome; SARS-CoV-2; Simvastatin | 2020 |
3 trial(s) available for amiodarone and simvastatin
| Article | Year |
|---|---|
Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers.
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Antidepressive Agents, Second-Generation; Area Under Curve; Cross-Over Studies; Double-Blind Method; Drug Interactions; Female; Fluoxetine; Gas Chromatography-Mass Spectrometry; Half-Life; Humans; Hypolipidemic Agents; Lactones; Lipase; Male; Middle Aged; Orlistat; Simvastatin | 2003 |
Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Area Under Curve; Biotransformation; Cross-Over Studies; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Polymorphism, Genetic; Pravastatin; Prospective Studies; Simvastatin; Tissue Distribution | 2007 |
Comparison of pharmacological and electrical cardioversion in permanent atrial fibrillation after prosthetic cardiac valve replacement: a prospective randomized trial.
Topics: Adult; Amiodarone; Anesthesia, General; Atrial Fibrillation; Captopril; Drug Therapy, Combination; Electric Stimulation; Female; Heart Valve Prosthesis; Humans; Male; Middle Aged; Mitral Valve; Prospective Studies; Simvastatin; Treatment Outcome | 2013 |
31 other study(ies) available for amiodarone and simvastatin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
Topics: Computational Biology; Cyclohexanols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Molecular Structure; Principal Component Analysis; Pyrrolizidine Alkaloids; Quantitative Structure-Activity Relationship; Reproducibility of Results; Substrate Specificity; Venlafaxine Hydrochloride | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Amiodarone's role in simvastatin-associated rhabdomyolysis.
Topics: Amiodarone; Anticholesteremic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Humans; Rhabdomyolysis; Simvastatin | 2003 |
Rhabdomyolysis in association with simvastatin and amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cytochrome P-450 Enzyme Inhibitors; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Rhabdomyolysis; Simvastatin | 2004 |
Adverse events with concomitant amiodarone and statin therapy.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Amiodarone; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Simvastatin; United States; United States Food and Drug Administration | 2005 |
Simvastatin interaction with clarithromycin and amiodarone causing myositis.
Topics: Amiodarone; Clarithromycin; Coronary Artery Bypass; Drug Interactions; Humans; Male; Middle Aged; Myositis; Pneumonia; Simvastatin; Tachycardia, Supraventricular | 2005 |
Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity.
Topics: Aged; Amiodarone; Chemical and Drug Induced Liver Injury; Drug Interactions; Humans; Male; Rhabdomyolysis; Simvastatin; Treatment Outcome; Uremia | 2006 |
Rhythm control for atrial fibrillation: non-channel antiarrhythmic drugs are en vogue.
Topics: Amiodarone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antioxidants; Atrial Fibrillation; Heart Conduction System; Heart Failure; Humans; Simvastatin | 2007 |
Rhabdomyolysis after addition of digitoxin to chronic simvastatin and amiodarone therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticholesteremic Agents; Digitoxin; Drug Interactions; Heart Failure; Humans; Male; Middle Aged; Rhabdomyolysis; Risk Factors; Simvastatin | 2007 |
Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Ambulatory Care; Amiodarone; Analysis of Variance; Aryl Hydrocarbon Hydroxylases; Brazil; Cohort Studies; Cytochrome P-450 CYP2C9; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ethnicity; Female; Genotype; Humans; Linear Models; Male; Middle Aged; Mixed Function Oxygenases; Multivariate Analysis; Pharmacogenetics; Polymorphism, Genetic; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Simvastatin; Treatment Outcome; Vitamin K Epoxide Reductases; Warfarin; Young Adult | 2008 |
These drugs don't mix.
Topics: Amiodarone; Drug Interactions; Enzyme Inhibitors; Humans; Hypolipidemic Agents; Rhabdomyolysis; Simvastatin; United States; United States Food and Drug Administration | 2008 |
Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone?
Topics: Amiodarone; Contraindications; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pyrazines; Renal Insufficiency; Rhabdomyolysis; Simvastatin; Sitagliptin Phosphate; Triazoles; United Kingdom; United States | 2009 |
Results of a safety initiative for patients on concomitant amiodarone and simvastatin therapy in a Veterans Affairs medical center.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Drug Interactions; Drug Labeling; Female; Follow-Up Studies; Hospitals, Veterans; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscular Diseases; Practice Patterns, Physicians'; Quality Assurance, Health Care; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2010 |
Simvastatin dosing restrictions; monitoring amiodarone therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Contraindications; Drug Interactions; Drug Monitoring; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2011 |
Effect of simvastatin-amiodarone drug interaction alert on appropriate prescribing.
Topics: Amiodarone; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Practice Patterns, Physicians'; Rhabdomyolysis; Simvastatin; United States; United States Food and Drug Administration | 2013 |
[Brown urine : Myoglobin-induced renal failure after concomitant administration of simvastatin and amiodarone].
Topics: Acute Kidney Injury; Aged; Amiodarone; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myoglobinuria; Renal Replacement Therapy; Rhabdomyolysis; Shock, Septic; Simvastatin | 2016 |
Gluteal rhabdomyolysis and renal failure due to simvastatin and amiodarone.
Topics: Amiodarone; Anti-Arrhythmia Agents; Buttocks; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Posture; Renal Insufficiency; Rhabdomyolysis; Risk Factors; Simvastatin; Time Factors; Tomography, X-Ray Computed | 2016 |
Exploring New Zealand prescription data using sequence symmetry analyses for predicting adverse drug reactions.
Topics: Aged; Amiodarone; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Humans; New Zealand; Pharmacoepidemiology; Simvastatin | 2017 |
Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.
Topics: Adult; Aged; Amiodarone; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrazoles; Pyridones; Rosuvastatin Calcium; Simvastatin | 2022 |